Safinamide (CAS 133865-89-1): Product Uses, Market Drivers and Supply Outlook
A market-oriented overview of safinamide uses, regulatory presence, quality expectations and Rlavie supply support.
Safinamide is a chiral active pharmaceutical ingredient used in Parkinson’s disease therapy in approved markets. Rlavie lists CAS 133865-89-1 for qualified pharmaceutical research, analytical and development requirements.
Product applications
Potential customer uses include formulation and analytical development, method verification, impurity studies, route evaluation and other controlled R&D activities. As a chiral API, safinamide also illustrates why identity, enantiomeric purity, related substances, residual solvents and solid-state considerations must be addressed together.
Market drivers
The long-term demand backdrop includes an aging population, continuing management of Parkinson’s disease and lifecycle activity across established therapies. Regulatory presence in major markets provides a verifiable foundation for development interest. Commercial opportunities will favor supply partners that can respond to project-specific specifications and documentation expectations.
Rlavie support
Rlavie can discuss intended use, specification alignment, available analytical documents, packaging and delivery requirements. Listing the compound does not mean that Rlavie supplies any marketed medicine; it means customers can approach Rlavie for a qualified material and project discussion.
The listed CAS identifies safinamide free base. Approved Xadago product information describes safinamide supplied as the mesilate salt. Match chemical form and assay basis to the development project; a catalog listing does not establish pharmaceutical-grade release or interchangeability with a finished medicine.
Products to evaluate for your project
Related Rlavie products
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
- EMA Xadago: approved safinamide medicine and product information
- WHO: Parkinson disease burden and treatment context
- FDA: Development of New Stereoisomeric Drugs
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.